PBYI on Nasdaq

Puma Biotechnology

American biopharmaceutical company

Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.³ From Wikipedia, CC BY-SA 4.0

$10.68 up 0.48 (4.71%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 18, 2026.

Overview

Compare with ANAPTYSBIO, INC, Akebia Therapeutics, Inc. or Ideaya Biosciences (United States), or pick any stock.

TickerPBYI on Nasdaq¹
Industrypharmaceutical industry¹
HeadquartersLos Angeles¹
Websitewww.pumabiotechnology.com
Incorporated inDE⁵
Business address10880 Wilshire Blvd., Suite 1700, Los Angeles, Ca⁵
Filer categoryAccelerated filer, Smaller reporting company⁵

See how the biggest companies compare on our leaderboards

Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.³

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

16.3%Operating margin⁷

13.6%Net margin⁷

-0.9%Revenue growth, 2025⁷

23.9%Return on equity⁷

0.00×Debt to equity⁷

$41.7MFree cash flow⁷

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 89% of the revenue Puma Biotechnology broke down this way in fiscal 2025.

Product$204.1M⁷89%up 5% from 2024
Royalty$24.3M⁷11%down 31% from 2024

Products and services by year

Products and services	2022	2023	2024	2025
Product		$203.1M	$195.2M	$204.1M
Royalty		$32.5M	$35.3M	$24.3M

Where the money goes

Where each dollar of revenue went, fiscal 2025

Cost of revenueSelling, general and adminOther costsProfit

Cost of revenue25¢$58.2M
Selling, general and admin31¢$70.8M
Other costs28¢$63.6M
Income tax2¢$4.7M
Profit14¢$31.1M

Out of $228.4M in revenue.⁷

Where each dollar of operating cash went, fiscal 2025

Kept or used elsewhere

Capital spending0¢$71.0K
Kept or used elsewhere100¢$41.7M

Out of $41.8M of cash from operations.⁷

Financial statements

Revenue⁸⁹¹⁰¹¹⁷$228.4M in 2025−16% since 2019

Operating income⁸⁹¹⁰¹¹⁷$37.3M in 2025

Net income⁸⁹¹⁰¹¹⁷$31.1M in 2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Total revenue	$228.4M	$230.5M	$235.6M
Cost of sales	$58.2M	$64.4M	$62.7M
Selling, general and administrative	$70.8M	$80.2M	$89.9M
Research and development	$62.1M	$54.9M	$50.4M
Total operating costs and expenses	$191.1M	$199.5M	$203.0M
Income from operations	$37.3M	$31.0M	$32.6M
Interest income	$4.1M	$4.7M	$2.6M
Interest expense	-$6.6M	-$12.5M	-$13.3M
Other income	$1.0M	$862.0K	$759.0K
Total other expenses, net	-$1.5M	-$6.9M	-$10.0M
Income Before Income Taxes	$35.8M	$24.1M	$22.7M
Current income tax (expense)	-$1.4M	-$897.0K	-$1.1M
Deferred income tax (expense) benefit	-$3.2M	$7.1M	$0
Net income	$31.1M	$30.3M	$21.6M
Net income per share of common stockbasic (in dollars per share)	$0.62	$0.62	$0.46
Net income per share of common stockdiluted (in dollars per share)	$0.61	$0.62	$0.45
Weighted-average shares of common stock outstandingbasic (in shares)	50.0M shares	48.6M shares	47.1M shares
Weighted-average shares of common stock outstandingdiluted (in shares)	50.7M shares	49.1M shares	47.6M shares

Total assets¹⁴⁸⁹¹⁰¹¹⁷$216.3M in 2025−8% since 2019

Total liabilities¹⁴⁸⁹¹⁰¹¹⁷$86.0M in 2025−60% since 2019

Shareholders’ equity⁹¹⁰¹¹⁷$130.3M in 2025+646% since 2019

Cash¹⁴⁸⁹¹⁰¹¹⁷$29.6M in 2025−51% since 2019

Long-term debt¹⁴⁸⁹¹⁰¹¹⁷$0 in 2025

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and cash equivalents	$29.6M	$69.2M
Marketable securities	$67.9M	$31.7M
Accounts receivable, net of allowance for credit loss of $0 and $362	$53.7M	$32.0M
Inventory	$5.5M	$8.7M
Prepaid expenses, current	$3.6M	$5.9M
Restricted cash, current	$2.1M	$0
Other assets, current	$256.0K	$91.0K
Total current assets	$162.7M	$147.7M
Lease right-of-use assets, net	$5.4M	$4.6M
Property and equipment, net	$187.0K	$515.0K
Intangible assets, net	$41.4M	$51.1M
Restricted cash, long-term	$0	$2.1M
Deferred tax assets	$3.8M	$7.1M
Prepaid expenses and other, long-term	$2.8M	$284.0K
Total assets	$216.3M	$213.3M
Accounts payable	$5.1M	$5.5M
Accrued expenses, current	$50.0M	$36.9M
Lease liabilities, current	$1.3M	$5.5M
Post-marketing commitment liability	$2.2M	$2.8M
Current portion of long-term debt	$22.5M	$45.3M
Other liabilities, current	$142.0K	$0
Total current liabilities	$81.3M	$96.1M
Lease liabilities, long-term	$4.7M	$1.5M
Post-marketing commitment liability, long-term	$0	$1.8M
Total long-term debt, net	$0	$21.7M
Other liabilities, long-term	$0	$121.0K
Total liabilities	$86.0M	$121.2M
Common stock - $.0001 par value per share; 100,000,000 shares authorized; 50,408,023 shares issued and outstanding at December 31, 2025 and 49,105,834 issued and outstanding at December 31, 2024	$5.0K	$5.0K
Additional paid-in capital	$1.4B	$1.4B
Accumulated other comprehensive income	$36.0K	$6.0K
Accumulated deficit	-$1.3B	-$1.3B
Total stockholders equity	$130.3M	$92.1M	$53.4M	$21.6M
Total liabilities and stockholders equity	$216.3M	$213.3M
Allowance for credit loss	$0	$362.0K
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	100.0M shares	100.0M shares
Common stock, shares issued (in shares)	50.4M shares	49.1M shares
Common stock, shares outstanding (in shares)	50.4M shares	49.1M shares

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and cash equivalents	$29.6M	$69.2M
Marketable securities	$67.9M	$31.7M
Accounts receivable, net of allowance for credit loss of $0 and $362	$53.7M	$32.0M
Inventory	$5.5M	$8.7M
Prepaid expenses, current	$3.6M	$5.9M
Restricted cash, current	$2.1M	$0
Other assets, current	$256.0K	$91.0K
Total current assets	$162.7M	$147.7M
Lease right-of-use assets, net	$5.4M	$4.6M
Property and equipment, net	$187.0K	$515.0K
Intangible assets, net	$41.4M	$51.1M
Restricted cash, long-term	$0	$2.1M
Deferred tax assets	$3.8M	$7.1M
Prepaid expenses and other, long-term	$2.8M	$284.0K
Total assets	$216.3M	$213.3M
Accounts payable	$5.1M	$5.5M
Accrued expenses, current	$50.0M	$36.9M
Lease liabilities, current	$1.3M	$5.5M
Post-marketing commitment liability	$2.2M	$2.8M
Current portion of long-term debt	$22.5M	$45.3M
Other liabilities, current	$142.0K	$0
Total current liabilities	$81.3M	$96.1M
Lease liabilities, long-term	$4.7M	$1.5M
Post-marketing commitment liability, long-term	$0	$1.8M
Total long-term debt, net	$0	$21.7M
Other liabilities, long-term	$0	$121.0K
Total liabilities	$86.0M	$121.2M
Common stock - $.0001 par value per share; 100,000,000 shares authorized; 50,408,023 shares issued and outstanding at December 31, 2025 and 49,105,834 issued and outstanding at December 31, 2024	$5.0K	$5.0K
Additional paid-in capital	$1.4B	$1.4B
Accumulated other comprehensive income	$36.0K	$6.0K
Accumulated deficit	-$1.3B	-$1.3B
Total stockholders equity	$130.3M	$92.1M	$53.4M	$21.6M
Total liabilities and stockholders equity	$216.3M	$213.3M
Allowance for credit loss	$0	$362.0K
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	100.0M shares	100.0M shares
Common stock, shares issued (in shares)	50.4M shares	49.1M shares
Common stock, shares outstanding (in shares)	50.4M shares	49.1M shares

Cash from operations⁸⁹¹⁰¹¹⁷$41.8M in 2025+87% since 2019

Capital spending⁸⁹¹⁰¹¹⁷$71.0K in 2025−77% since 2019

Free cash flow⁸⁹¹⁰¹¹⁷$41.7M in 2025+89% since 2019

Every line of the cash flow as filed: the last 3 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Net income	$31.1M	$30.3M	$21.6M
Depreciation and amortization	$10.9M	$11.5M	$11.5M
Stock-based compensation	$6.9M	$8.2M	$10.2M
Deferred income taxes	$3.2M	-$7.1M	$0
Provision for credit loss recovery	-$362.0K	-$519.0K	$881.0K
Loss on disposal of property and equipment	$4.0K	$0	$0
Loss on impairment of asset	$0	$0	$625.0K
Accounts receivable, net	-$21.3M	$16.3M	-$8.4M
Inventory, net	$3.2M	-$1.6M	-$2.6M
Prepaid expenses and other	-$325.0K	$1.0M	$820.0K
Other current assets	-$165.0K	$821.0K	$1.5M
Accounts payable	-$453.0K	-$1.4M	$449.0K
Operating lease assets and liabilities, net	-$1.8M	-$1.6M	-$1.2M
Accrued expenses and other	$13.2M	-$15.8M	-$7.6M
Post-marketing commitment liability	-$2.4M	-$1.3M	-$940.0K
Net cash provided by operating activities	$41.8M	$38.9M	$27.0M
Purchase of property and equipment	-$71.0K	-$56.0K	-$140.0K
Purchase of available-for-sale securities	-$108.1M	-$76.2M	-$23.8M
Maturity of available-for-sale securities	$72.0M	$55.8M	$17.3M
Purchase of intangible assets	$0	$0	-$12.5M
Net cash used in investing activities	-$36.2M	-$20.4M	-$19.1M
Net proceeds from shares issued under employee stock plans	$130.0K	$150.0K	$0
Payment of debt	-$44.4M	-$33.3M	$0
Payment of exit costs	-$888.0K	-$666.0K	$0
Net cash used in financing activities	-$45.2M	-$33.8M	$0
Net (decrease) increase in cash, cash equivalents and restricted cash	-$39.6M	-$15.4M	$7.9M
Property and equipment purchases in accounts payable	$5.0K	$0	$26.0K
Interest paid	$5.8M	$10.8M	$11.6M
Income taxes paid	$1.5M	$1.2M	$737.0K

Compare Puma Biotechnology with another company

The story

Puma was founded in September 2010 by Alan Auerbach to identify and in-license compounds that were already in clinical development. This was the same business plan Auerbach had followed at Cougar Biotechnology, which he founded in 2003, and through which he in-licensed abiraterone acetate from BTG plc. Cougar further developed abiraterone before the company was sold to Johnson & Johnson in 2009. Auerbach brought many Cougar employees with him after founding Puma in 2010.

From Wikipedia’s article on Puma Biotechnology, shared under CC BY-SA 4.0.⁶

Leadership

Who has led Puma Biotechnology, and when. Pick a name to see everywhere that person has worked.

2010201520202025

Chief executive officerAlan H. Auerbach Oct 11, 2011 to now¹⁵
PresidentAlan H. Auerbach Oct 11, 2011 to now¹⁵
Chief financial officerMaximo F. Nougues Nov 13, 2018 to now¹⁶

Board members and other officers (21)

Chief Scientific OfficerAlvin F. Wong Jun 22, 2021 to Feb 14, 2024¹⁷
Chief Commercial OfficerJeffrey Jerome Ludwig Mar 23, 2020 to Feb 11, 2025¹⁸
OfficerDouglas M. Hunt Jan 8, 2018 to now¹⁹
OfficerRobert Charnas Feb 21, 2017 to Feb 21, 2017²⁰
Chief Commercial OfficerSteven Lo Sep 10, 2015 to Jul 24, 2019²¹
SR VP, CLINICAL RESEARCH & DEVRichard Paul Bryce Jun 28, 2012 to Apr 6, 2021²²
SR. VP-FINANCE & TREASURERCharles R. Eyler Oct 11, 2011 to Feb 6, 2019²³
SecretaryFaraaz Siddiqi Nov 20, 2007 to Nov 20, 2007²⁴
Board memberAlessandra Cesano Aug 2, 2022 to now²⁵
Board memberAllison Dorval Jul 16, 2021 to now²⁶
Board memberBrian M. Stuglik Jul 7, 2020 to now²⁷
Board memberHugh O'Dowd Oct 17, 2019 to Jun 11, 2020²⁸
Board memberAnn Calby Miller Nov 13, 2019 to Jun 17, 2021²⁹
Board memberAdrian Senderowicz Aug 13, 2015 to now³⁰
Board memberFrank Zavrl Sep 10, 2015 to Jun 11, 2020³¹
Board memberTroy Edward Wilson Oct 21, 2013 to now³²
Board memberJay M. Moyes Apr 30, 2012 to now³³
Board memberAlan H. Auerbach Oct 11, 2011 to now¹⁵
Board memberThomas Malley Oct 11, 2011 to Dec 16, 2014³⁴
Board memberKapil Munjal Nov 16, 2007 to Nov 16, 2007³⁵
Board memberFaraaz Siddiqi Nov 20, 2007 to Nov 20, 2007²⁴

Former names

INNOVATIVE ACQUISITIONS CORPSep 14, 2007 to Oct 4, 2011⁵

Timeline

Oct 11, 2011New chief executive Alan H. Auerbach becomes CEO¹⁵

Filings

361 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 48 major events, 173 insider forms, 29 large holders, 90 other. The latest 20:

Oct 6, 2026SCHEDULE 13D/A EDGAR
Sep 16, 20264 EDGAR
Sep 16, 20264 EDGAR
Sep 14, 2026144 EDGAR
Sep 14, 2026144 EDGAR
Aug 6, 202610-Q EDGAR
Aug 6, 20268-K EDGAR
Jul 8, 20264 EDGAR
Jul 8, 20264 EDGAR
Jul 8, 20264 EDGAR
Jul 6, 2026144 EDGAR
Jul 6, 2026144 EDGAR
Jul 6, 2026144 EDGAR
Jun 16, 20268-K EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR

The 361 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 29 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Acorn Capital Advisors, LLC	4,131,299	$33.5M	9.1%	No change
BlackRock, Inc.	3,804,736	$30.9M	0.0%	+205,784
American Century Companies Inc	2,319,996	$18.8M	0.0%	+403,650
Renaissance Technologies LLC	1,836,213	$14.9M	0.0%	−106,200
Vanguard Capital Management LLC	1,835,643	$14.9M	0.0%	+17,962
Vanguard Portfolio Management LLC	1,825,599	$14.8M	0.0%	+90,950
Dimensional Fund Advisors LP	1,518,014	$12.3M	0.0%	+81,908
Geode Capital Management, LLC	1,339,405	$10.9M	0.0%	+322,063
O'shaughnessy Asset Management, LLC	1,123,783	$9.1M	0.0%	−14,386
State Street Corp	952,165	$7.7M	0.0%	+34,575
Kennedy Capital Management LLC	873,253	$7.1M	0.1%	−16,348
Bridgeway Capital Management, LLC	791,616	$6.4M	0.1%	+16,275
Ritholtz Wealth Management	749,798	$6.1M	0.1%	−24,510
Aqr Capital Management LLC	725,192	$5.9M	0.0%	−75,002
Goldman Sachs Group Inc	669,156	$5.4M	0.0%	−563
Northern Trust Corp	652,386	$5.3M	0.0%	+10,633
Connor, Clark & Lunn Investment Management Ltd.	642,946	$5.2M	0.0%	−139,852
UBS Group AG	636,761	$5.2M	0.0%	+102,534
Millennium Management LLC	602,240	$4.9M	0.0%	−875,279
Arrowstreet Capital, Limited Partnership	532,450	$4.3M	0.0%	−5,705
Sei Investments Co	418,669	$3.4M	0.0%	−89,513
Globeflex Capital L P	382,807	$3.1M	0.4%	+33,156
Bank of New York Mellon Corp	360,734	$2.9M	0.0%	+12,853
D. E. Shaw & Co., Inc.	316,343	$2.6M	0.0%	−34,892
State Board Of Administration Of Florida Retirement System	309,106	$2.5M	0.0%	+36,216

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

2 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

Date	Member	Trade	Amount	Vs S&P since	Filing
May 15, 2019	Donna Shalala, House	Sale	$1,001 - $15,000	+207.3%	Report
Jan 23, 2019	Donna Shalala, House	Buy	$1,001 - $15,000	−250.2%	Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataPuma Biotechnology on Wikidata
2
SEC EDGARPuma Biotechnology filings on SEC EDGAR
3
WikipediaPuma Biotechnology on Wikipedia
4
Yahoo FinancePBYI quote
5
SEC EDGARPuma Biotechnology filings on SEC EDGAR
6
WikipediaPuma Biotechnology on Wikipedia (revision used)
7
SEC EDGARPuma Biotechnology 10-K for fiscal 2025
8
SEC EDGARPuma Biotechnology 10-K for fiscal 2019
9
SEC EDGARPuma Biotechnology 10-K for fiscal 2020
10
SEC EDGARPuma Biotechnology 10-K for fiscal 2021
11
SEC EDGARPuma Biotechnology 10-K for fiscal 2022
12
SEC EDGARPuma Biotechnology 10-Q for fiscal 2026
13
SEC EDGARPuma Biotechnology 10-Q for fiscal 2026
14
SEC EDGARPuma Biotechnology 10-K for fiscal 2019
15
SEC EDGARAlan H. Auerbach, Chief executive officer
16
SEC EDGARMaximo F. Nougues, Chief financial officer
17
SEC EDGARAlvin F. Wong, Chief Scientific Officer
18
SEC EDGARJeffrey Jerome Ludwig, Chief Commercial Officer
19
SEC EDGARDouglas M. Hunt, Officer
20
SEC EDGARRobert Charnas, Officer
21
SEC EDGARSteven Lo, Chief Commercial Officer
22
SEC EDGARRichard Paul Bryce, SR VP, CLINICAL RESEARCH & DEV
23
SEC EDGARCharles R. Eyler, SR. VP-FINANCE & TREASURER
24
SEC EDGARFaraaz Siddiqi, Secretary
25
SEC EDGARAlessandra Cesano, Board member
26
SEC EDGARAllison Dorval, Board member
27
SEC EDGARBrian M. Stuglik, Board member
28
SEC EDGARHugh O'Dowd, Board member
29
SEC EDGARAnn Calby Miller, Board member
30
SEC EDGARAdrian Senderowicz, Board member
31
SEC EDGARFrank Zavrl, Board member
32
SEC EDGARTroy Edward Wilson, Board member
33
SEC EDGARJay M. Moyes, Board member
34
SEC EDGARThomas Malley, Board member
35
SEC EDGARKapil Munjal, Board member